Introduction to B-cell Siglecs
B cells are an important part of the adaptive immune system and generate the humoral immune response by secretion of antigenspecific antibodies. The signaling by the B-cell antigen receptor (BCR), induced by antigen binding is crucial for triggering B-cell development, B-cell activation, as well as differentiation to antibody-secreting plasma cells. Accessory transmembrane molecules or co-receptors on the B-cell surface modulate BCR signaling. These B-cell co-receptors can be activatory or inhibitory and fulfil these functions by binding additional signaling proteins with their intracellular tails and thereby recruiting these effectors into the vicinity of the BCR. Very often the activity of co-receptors is regulated by extracellular-bound ligands, which determine the association of the co-receptors to the BCR. B-cell immunity depends on recognition of foreign antigens and a lack of responsiveness to self-antigens. Although central B-cell tolerance is induced in the bone marrow by several mechanisms, many peripheral B cells in the periphery escape these tolerance mechanisms, produce self-reactive antibodies and need to be controlled by peripheral tolerance mechanisms in order to prevent autoimmunity (Wardemann et al. 2003) . Inhibitory co-receptors on B cells contribute to this control of B-cell tolerance.
CD22 (Siglec-2) and Siglec-G (or its human ortholog Siglec-10) are two B-cell expressed members of the Siglec (sialic acid-binding immunoglobulin (Ig)-like lectin) family and have been shown to negatively regulate BCR signaling (Jellusova and Nitschke 2012) . Both are associated to some extent with the BCR (Peaker and Neuberger 1993; Zhang and Varki 2004; Müller et al. 2013) and are inhibitory co-receptors. Both Siglecs carry intracellular inhibitory ITIMs (immunoreceptor tyrosine-based inhibition motifs) and recruit the tyrosine phosphatase SHP-1 that inhibits signaling (Doody et al. 1995; Pfrengle et al. 2013 ). The inhibitory functions of both Siglecs are regulated by ligand binding (Hutzler et al. 2014) . Both Siglecs bind to sialic acids in specific linkages, which are attached to glycoproteins and which are present on cellular surfaces, including the B-cell surface. The presence or absence of these ligands regulates the association of these two Siglecs to the BCR and thus influences the strength of inhibition. Since sialic acids are abundantly expressed in vertebrates, but often not found on microorganisms they are a part of "selfstructures" and there is evidence that the sialic acid binding by B-cell Siglecs regulates B-cell tolerance and prevents autoimmunity ).
Regulation of B-cell signaling
CD22 and Siglec-G are the only two Siglecs which are expressed on murine B cells. Human B cells express CD22, Siglec-10, as well as Siglec-6 (Crocker et al. 2007 ). CD22 has a very B-cell restricted expression pattern (Torres et al. 1992 ). An expression and function outside of the B-cell lineage has only been shown on intestinal eosinophils and on a DC subpopulation (Wen et al. 2012; Ma et al. 2013) . Also Siglec-G shows the highest expression pattern on B cells; however, it is also expressed on dendritic cells (DCs) and eosinophils as shown by use of newly generated monoclonal anti-Siglec-G antibodies Hutzler et al. 2014) . Both Siglecs are able to associate to the BCR on B cells and inhibit BCR-mediated signaling. While both Siglecs can inhibit BCR signaling on B cells, Siglec-G deficient mice show that Siglec-G is mainly a non-redundant inhibitory receptor on B-1 cells, a B-cell subpopulation with special functions (Ding et al. 2007; Hoffmann et al. 2007 ). In contrast, CD22 seems to be the dominant inhibitory Siglec for conventional B cells (also called B-2 cells). However, when transfected into a chicken B-cell line, which resembles immature conventional B cells, Siglec-G can also inhibit surface (s)IgM-triggered signaling there (Hoffmann et al. 2007 ). Also when mouse B cells are treated with highaffinity Siglec-G ligands, BCR signaling can be suppressed in conventional B cells ). The inhibitory signaling by CD22 and Siglec-G has been the subject of several recent reviews and will therefore be covered here only briefly (Nitschke 2009; Jellusova and Nitschke 2012) .
The signaling function of CD22 has been dissected in detail by several groups. The intracellular tail of CD22 carries six tyrosines, which are the only known signaling modules of CD22. Three tyrosines are found within conventional ITIMs (Y783, Y843 and Y863), one is part of an ITIM-like motif (Y817) and one is a Grb-2 binding motif (Y828) (Doody et al. 1995; Otipoby et al. 2001) (Figure 1 ). Upon BCR cross-linking CD22 is rapidly phosphorylated by the Src kinase Lyn (Smith et al. 1998) . The phosphorylated ITIM residues of the CD22 tail are bound by the tyrosine phosphatase SHP-1, a central inhibitory signaling molecule (Doody et al. 1995) . SHP-1 is the main downstream effector of CD22 and CD22-deficient B cells show increased tyrosine phosphorylation of several proteins which are involved in triggering proximal BCR signaling responses, such as SLP65/BLNK, Vav1 and CD19 (Fujimoto et al. 1999; Gerlach et al. 2003) . Correspondingly, BCR-induced Ca2+ signaling is strongly enhanced in Cd22−/− B cells (O'Keefe et al. 1996; Otipoby et al. 1996; Sato et al. 1996; Nitschke et al. 1997) . A second phosphatase, the inositol phosphatase SHIP, can also be bound to the tyrosine phosphorylated CD22 tail in a complex with the adaptor proteins Grb2 and Shc, but has a so far unknown function (Poe et al. 2000) . The CD22 ITIM motifs are critical for the inhibitory function of CD22, as has been shown in B-cell lines, but also recently in mice in which the three ITIM tyrosines were mutated (Müller et al. 2013 ). These CD22 ITIM-mutated knockin mice (called CD22-Y2,5,6F mice, for mutations in the 2nd, 5th and 6th tyrosine of the three ITIMs) had a similar phenotype as CD22-deficient mice.
Siglec-G is a negative regulator of Ca 2+ signaling specifically in B-1 cells, as Siglecg−/− mice have a B-1-cell restricted phenotype and Siglecg−/− B-1 cells show increased anti-IgM-induced Ca2+ signaling, in contrast to B-2 cells of these mice (Hoffmann et al. 2007 ). Siglec-G and the human ortholog Siglec-10 both have one ITIM and one ITIM-like sequence and can bind SHP-1 (as shown for Siglec-G) or SHP-1 and the related phosphatase SHP-2 (as shown for Siglec-10) (Whitney et al. 2001) . How these SHP phosphatases regulate downstream signaling in B-1 cells is not known in detail as crucial signaling molecules which are part of the BCR signalosome, such as PLCγ, Btk or SLP65/BLNK showed unchanged tyrosine phosphorylation in Siglecg−/− B-1 cells (Hoffmann et al. 2007 ). The transcription factor NFATc1 has elevated expression levels in Siglecg−/− B-1 cells, which could be an autoregulatory process due to increased Ca2+ signaling (Jellusova and Nitschke 2012) . One study also reported increased NF-kB activation in Siglecg−/− B-1 cells, a finding that was not confirmed by another group (Ding et al. 2007; Jellusova and Nitschke 2012) .
Both CD22 and Siglec-G also modulate TLR signaling in B cells. TLRs are pattern recognition receptors for bacterial or viral . CD22 forms homo-oligomers by binding to 2,6Sia (α2,6-linked sialic acids) on neighboring CD22 molecules. These CD22 homo-oligomers are normally separated from the BCR. Upon antigen binding, CD22 homo-oligomers are recruited to the BCR (indicated by red arrow), this leads to phosphorylation of ITIMs (immunoreceptor tyrosine-based inhibitory motifs) (indicated by Y in green boxes in the tail) in the intracellular tail of CD22. SHP-1 is recruited to the phosphorylated ITIMs and inhibits Ca 2+ signaling. (B) Siglec-G mainly inhibits Ca 2+ signaling in B-1 cells. Studies with Siglec-G ligand-binding mutants mice indicate that Siglec-G binds directly to glycosylated IgM via 2,6Sia or 2,3Sia (α2,3-linked sialic acid) binding. Siglec-G or the human ortholog Siglec-10 recruits SHP-1 to its phosphorylated ITIM. BCR: B-cell receptor, Y denotes a tyrosine residue in the Siglec tail. P denotes phosphorylation of tyrosines in ITIMs.
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products. TLRs are expressed on cells of the innate immune system, but are also present on B cells. Both Siglec-G-deficient and CD22-deficient B cell showed increased proliferative responses when stimulated with TLR4, TLR7 or TLR9 ligands (Kawasaki et al. 2011; Jellusova and Nitschke 2012) . The exact mechanism of the negative regulation of TLR responses is not known; however, CD22 could inhibit TLR-4-dependent NF-kB activation and could reduce TLR-induced expression of SOCS1 and SOCS3 (Kawasaki et al. 2011 ). SOCS1 and SOCS3 are inhibitors in TLR-induced signaling. The negative regulation by Siglecs on TLR signaling was also found for other Siglecs that are expressed on cells of the innate immune system. Siglec-E has been shown to bind to SHP-1 and SHP-2 after LPS stimulation and to inhibit TLR-mediated NF-kB activation after antibodyinduced Siglec-E cross-linking (Blasius et al. 2006; Boyd et al. 2009 ). This indicates a possible signaling pathway that may also apply for CD22 and Siglec-G. Since upregulated TLR-7 signaling or co-engagement of TLR-7 and BCR has been linked to induction of autoimmunity (Viglianti et al. 2003; Deane et al. 2007 ), enhanced TLR B-cells responses of Siglec-deficient B cells may contribute to occurrence of autoimmunity.
B-cell development and immune responses in gene-targeted mice with mutated Cd22 or Siglecg genes
Siglec-G is expressed from the pro-B-cell stage throughout the whole B-cell lineage with slightly higher levels on immature, B-1 or Marginal zone B cells than on follicular mature B cells, as found with new monoclonal antibodies Hutzler et al. 2014) . Similarly, CD22 is expressed from pre-B cells onwards throughout the B-cell development (Torres et al. 1992) . Both molecules seem not to be important for early B-cell development, as neither CD22-nor Siglec-G-deficient mice show impairment of B-cell differentiation in the bone marrow.
CD22-deficient mice have a lower percentage of immature transitional B cells and a higher percentage of mature B cells in the spleen. Splenic B cells also express higher levels of MHC class II, which is an activation marker on B cells (Otipoby et al. 1996; Nitschke et al. 1997; Gerlach et al. 2003) . Both phenotypes indicate that Cd22−/− B cells are preactivated due to stronger BCR signaling. Although mature follicular B cells are found in normal numbers in the spleen or lymph nodes of Cd22−/− mice, they show an increased apoptosis rate in vitro and a higher turnover in vivo, as indicated by BrdU incorporation (Otipoby et al. 1996; Nitschke et al. 1997) . Recently, CD22 knockin mice were generated in which Arg 130 was mutated, a critical residue for sialic acid binding (CD22-R130E) or where the three ITIM motifs were mutated (CD22-Y2,5,6F) ( Table I) . CD22-Y2,5,6F mice showed increased B-cell turnover and decreased survival, similar to KO mice, while both was unchanged in CD22-R130E mice (Müller et al. 2013) . Also previously generated ligand-binding mutant mice with mutated Arg130 and Arg137 (CD22-R130,137A) showed unchanged B-cell turnover, while mice with deleted first and second Ig-domains of CD22 (Cd22-D1-2), which are also defective in Sia binding surprisingly had increased B-cell turnover (Poe et al. 2004) . Overall, these data show that the impaired B-cell survival and increased B-cell turnover is dependent on the ITIM-signaling domain, but not on ligand binding (Table I) . 
MZ, B-1, recirc, number of MZ B cells, B-1 cells or recirculating B cells in the bone marrow, respectively; CD22 expr, CD22 expression level on B cells; BrdU incorp, BrdU incorporation as measurement of B-cell turnover; BCR Ca2+, BCR-induced Ca2+ signaling; Siglec-IgM assoc., association of CD22 or Siglec-G to mIgM; Anti-IgM prolif, anti-IgM-induced proliferation; TLR-ind prolif, TLR-induced proliferation of B cells; TD resp, TI resp, response to T-cell dependent or T-cell independent antigens; respectively: auto-AB, autoantibodies;
↓, decreased; ↑, increased; norm, normal; n.r., not relevant; n.d., not determined. If two phenotypes are given, two or more mouse strains show variations. References for these phenotypes are given in the text.
CD22 and Siglec-G on B cells
Despite these changes in B-cell turnover and despite changes in B-cell signaling, CD22-deficient mice can mount normal T-cell dependent immune responses (Otipoby et al. 1996; Sato et al. 1996; Nitschke et al. 1997) . This is probably due to T-cell help, which can overcome the changed BCR signaling and apoptosis sensitivity. In support of this anti-IgM-induced proliferation of Cd22−/− B cells is impaired, while anti-CD40 stimulation is normal (Table I) . However, one study showed in a BCR-transgenic mouse line that germinal centers (GC) formed earlier and GC B cells proliferated stronger in a T-cell dependent response, if CD22 was absent (Onodera et al. 2008 ). This shows that under some conditions the loss of CD22 and increased BCR signaling can drive B cells into earlier immune responses.
Although CD22-deficient mice have normal mature follicular B cells in spleen and lymph nodes, these cells are strongly reduced in the bone marrow (Nitschke et al. 1997) . Since the majority of mature B cells in the bone marrow are recirculating B cells, i.e., cells that have matured in the spleen and migrate back to the bone marrow, this indicated a migration or a survival defect. First experiments indicated a migration defect of Cd22−/− B cells, as bone marrow endothelium expresses the CD22 ligands: 2,6-linked sialic acids (2,6Sia) and transfer experiments of Cd22−/− B cells showed a migration defect to the bone marrow (Nitschke et al. 1999) . However, mouse models with mutated CD22 ligand-binding domains did not generally show the defect of mature B cells in the bone marrow. Furthermore, transfer experiments of B cells with mutant CD22 ligand-binding domains did not lead to impaired migration to the bone marrow (Poe et al. 2004; Müller et al. 2013 ). In contrast, ITIM-mutated CD22-Y2,5,6F mice showed a reduced recirculating B-cell population in the bone marrow and also a migration defect upon transfer (Table I) . Since B-cell survival is impaired in CD22-Y2,5,6F mice, it is likely that the defect of bone marrow recirculating B cells in CD22-deficient mice is due to impaired B-cell survival, but not to ligand interactions to bone marrow endothelium (Müller et al. 2013 ).
CD22-deficient mice have a strong reduction of marginal zone (MZ) B cells in the spleen (Samardzic et al. 2002) . These MZ B cells are found outside B-cell follicles and are important for T-cell independent antigen responses. These responses are reduced in CD22-deficient mice. Both CD22 knockin mice with mutated ITIM motifs or mutated ligand-binding domains show a comparable MZ B-cell defect (Poe et al. 2004; Müller et al. 2013) . This suggests that the BCR signaling response, which is normally modulated by CD22, as well as on possible ligand interactions of CD22 to 2,6Sia-expressing cells in the spleen regulate generation, maintenance or correct location of MZ B cells. Altered chemokine responsiveness of CD22-deficient B cells may play a role in this MZ B-cell defect (Samardzic et al. 2002) , but further mechanistic details are unclear.
Recently, the first monoclonal antibodies against Siglec-G were developed. Studies with both of these antibodies showed a quite uniform expression of Siglec-G on the membrane of all types of B cells, with just marginally higher levels on B-1 cells in the peritoneum than on B-2 cells Hutzler et al. 2014) . Therefore, it is quite surprising that Siglecg−/− mice show a B-1-cell restricted phenotype, not affecting the population of conventional B-2-cells. The population of B-1 cells is strongly enlarged in Siglecg−/− mice (Hoffmann et al. 2007 ).
B-1 cells are a special B-cell population, which is found at unique locations, such as in the peritoneal and pleural cavity, is largely derived from fetal liver precursors and produces Igs with a restricted Ig repertoire. B-1 cells are responsible for secreting the so-called natural antibodies of the class IgM which are important for early anti-bacterial responses and are also thought to fulfill house-keeping functions, e.g., in clearance of apoptotic cells (Baumgarth 2011) . In the mouse, two populations of B-1 cells can be found, the B-1a cells which are CD5
+ and the B-1b cells which are CD5 − . Siglec-G-deficient mice have increased populations of both B-1 cell subsets, but particularly strongly increased B-1a cell numbers. This B-1-cell expansion is B-1-cell intrinsic, as has been shown by mixed chimaera experiments with adoptive transfers of bone marrow cells (Hoffmann et al. 2007 ). B-1 cells are a population that has self-renewing capacity and the maintenance of this population depends on BCR signaling. Therefore, Siglecg−/− B-1 cells, which show stronger BCR-induced Ca2+ signaling obtain a stronger survival/proliferation signal which partly explains their higher numbers. This was also directly demonstrated as Siglecg−/− B-1 cells show increased survival in vitro and after adoptive transfer to RAG1−/− mice in vivo, when compared with WT B-1 cells (Jellusova, Duber, et al. 2010) . The exact signaling pathway leading to increased survival of Siglec-G-deficient B-1 cells is not known, but might include the overexpression of NFATc1. NFATc1 is crucial for B-1-cell survival as has been shown in NFATc1-deficient mice (Berland and Wortis 2003) .
Siglec-G-deficient mice have an enlarged B-1-cell population and these B-1 cells also show shifts in the produced Ig repertoire. B-1 cells have a restricted VDJ segment usage producing antibodies dominated by specificities for common bacterial structures and also self-antigens. Siglecg−/− B-1 cells showed interesting changes in the Ig repertoire (Jellusova, Duber, et al. 2010 ). When B-1 cells of Siglec-G-deficient mice were stained with typical antigens recognized by mIgM on B-1 cells, such as phosporylcholine (PC) or phosphatidylcholine, a lower percentage of these cells was found. However, IgM serum levels of Siglecg−/− mice are 10-fold increased, so overall typical secreted anti-PC antibodies or antibodies against oxidized lipoproteins, which are beneficial during artherogenic responses are normal or even increased in frequency (Jellusova, Duber, et al. 2010) .
Since Siglec-G does not show a B-1-cell restricted expression within the B-cell lineage, it was unclear why Siglec-G-deficient mice show a B-1-cell restricted phenotype. Recently, mice with a mutated ligand-binding domain of Siglec-G were generated (Siglec-G R120E mice) and these mice showed a very similar phenotype to Siglec-G-deficient mice: Increased B-1 cell numbers, increased Ca 2+ responses just in B-1 cells, increased serum IgM levels and similar changes in the Ig repertoire of B-1 cells (Hutzler et al. 2014) (Table I ). These data suggested that the ligand-binding domain of Siglec-G is crucial for the functions of this protein on B-1 cells. The mechanistic details of this are discussed in the following.
Ligand interactions of CD22 and Siglec-G
While it is well established that CD22 and Siglec-G are both inhibitory receptors on B cells, the important questions remain, L Nitschke why does this inhibitory function exist, under which physiological situation is the inhibitory signaling needed and how is this inhibitory signaling regulated? Recent studies with new genetic mouse models show that ligand binding plays an important role in this regulation. The first Ig-domain of both CD22 and Siglec-G mediates binding to sialic acids. CD22 binds sialic acids in the α2,6 linkage (2,6Sia) to galactose that is further attached to the core glycans of glycoproteins (Powell et al. 1993; Kelm et al. 1994; Engel et al. 1995) . In contrast, Siglec-G binds both 2,6Sia and α2,3-linked sialic acids (2,3Sia) (Duong et al. 2010) . These sialic acids occur on many soluble glycoproteins in blood plasma, such as haptoglobulin or IgM (Hanasaki et al. 1995; Adachi et al. 2012) . Sialic acids are also abundantly expressed on the surface of many human or murine cells. CD22 and Siglec-G can therefore potentially engage in many interactions and bind sialylated glycoproteins on other cells (in trans) or on the B-cell surface itself (in cis). Which of these interactions can occur in vivo and which of these are physiologically relevant is still an important issue of ongoing research.
The abundant expression of sialic acids on the cell surface of cells of the immune system seems to "mask" most Siglec proteins (Razi and Varki 1998) . This means that the Siglec proteins are bound by cis-ligands, which limits their accessibility to trans-ligands. This seems to be a general property within the Siglec family. The masking of Siglecs by cis-ligands does not mean that trans-interactions are not possible. This is probably a dynamic process of competitive sialic acid-binding in cis or in trans, which depends on ligand availability and affinity, steric accessibility and cell-cell contacts. It has been demonstrated that CD22 can bind in cis to IgM or CD45 (Zhang and Varki 2004) . The proximity of CD22 to the BCR is crucial for the CD22 inhibitory function. However, only a small fraction of CD22 molecules on the B-cell surface is associated with the BCR (Peaker and Neuberger 1993) . As the interaction of CD22 with mIgM or CD45 on B cells is not lost upon sialidase treatment or upon mutation of Arg130, a critical amino acid for sialic acid binding, these interactions are sialic acid independent and are likely protein-protein interactions (Zhang and Varki 2004) . Instead, CD22 binds to other sialylated CD22 molecules, forming oligomers on the B-cell surface, as has been demonstrated by a photoaffinity cross-linking approach (Han et al. 2005) . These CD22 oligomers seem to be distinct from the BCR on distinct membrane domains (Figure 1 ). An increased association of CD22 with mIgM after BCR stimulation suggests a recruitment of these CD22 oligomers to mIgM molecules (Müller et al. 2013) .
How does this homo-oligomer formation of CD22 molecules affect the regulation of BCR signaling? Two genetic approaches show that when CD22-ligand interactions on the B-cell surface are disrupted a stronger association of CD22 with mIgM occurs and a stronger inhibition of Ca2+ signaling results. The first approach is the knockout of the gene coding for ST6GalI, the enzyme that creates 2,6Sia linkages on glycoproteins. In this case, a higher CD22-IgM association, a stronger CD22 tyrosine phosphorylation and an impaired BCR-induced Ca2+ signaling was reported (Collins, Smith, et al. 2006; Grewal et al. 2006) . Similarly, CD22-R130E mice with a mutated ligand-binding domain showed higher IgM-CD22 association, a higher tyrosine phosphorylation of CD22, a stronger SHP-1 recruitment and a strongly impaired mIgM-triggered Ca2+ response (Müller et al. 2013) (Table I) . Surprisingly, two other mouse models with mutated CD22 ligand-binding domains (CD22-R130,137A and CD22-Δ1-2) did not show this impaired Ca2+ signaling (Poe et al. 2004) . One possibility to explain this difference is that in the latter two mouse strains the surface expression of CD22 was reduced to 50%, maybe due to the introduced mutations. So two effects (stronger association to the BCR and reduced surface expression) may compensate each other in this case.
For Siglec-G much less is known concerning possible cis-ligands. This is due to the fact that less tools, i.e., antibodies for immuno-precipitations, etc., exist. However, recently, a mouse model with a mutated ligand-binding domain of Siglec-G (Siglec-G R120E mice) was published (Hutzler et al. 2014 ). This mouse model showed that apparently the association of Siglec-G to mIgM is regulated quite differently from the association of CD22 to IgM. A proximity-ligation experiment showed that Siglec-G is normally associated with mIgM, an interaction, which can be further increased upon BCR stimulation. Surprisingly, this interaction was almost completely gone in Siglec-G R120E B cells. There was also an interesting difference found between B-1 cells and B-2 cells. B-1 cells expressed more 2,3 Sia on the surface, thus potential Siglec-G ligands, than B-2 cells (Hutzler et al. 2014) . Since also the association of Siglec-G with mIgM was higher on B-1 cells than on B-2 cells, these data suggest a direct Siglec-G binding to sialylated IgM, preferentially on B-1 cells (Figure 1) . Accordingly, Siglec-G R120E mice showed enhanced B-1 cell Ca2+ signaling, but normal B-2 cell Ca2+ signaling, similar to Siglec-G-deficient mice. Also all other phenotypes affecting only B-1 cells were found similarly in both mouse strains (Hutzler et al. 2014) . These data suggest that Siglec-G is recruited to mIgM by direct sialic acid binding and that sialic acid-binding positively regulates its function.
In addition to cis-binding, CD22 on B cells can also be engaged in trans-interactions to ligands on other cells. This has been discussed to be relevant for homotypic B-cell-B-cell or for B-cell-T-cell interactions. B-cell interactions with other cells that express a cell-bound antigen together with 2,6Sia can lead to suppression of B-cell signaling and B-cell proliferation in a CD22-dependent way (Lanoue et al. 2002) (Figure 2) . Also, ST6GalI-deficient B cells show an even CD22 distribution on the cells surface; however, when in contact with wildtype B cells, CD22 is distributed to the cell contact side by binding to trans-ligands (Collins et al. 2004) . In a proteomic approach, one study identified trans-ligands for CD22 by glycan-protein cross-linking. From opposing B cells, mIgM was detected as a major in situ trans-ligand for CD22 (Ramya et al. 2010) . It has also been demonstrated that soluble glycosylated pentameric IgM can be recognized by CD22 and in complex with antigen can suppress B-cell responses (Adachi et al. 2012) . Early studies also suggested that CD45 on T cells could be a trans-ligand for CD22 (Sgroi et al. 1995) . It is so far unknown what the physiological role of these natural transligands is. However, synthetic high-affinity trans-ligands for CD22 or Siglec-G attached to liposomes or to high-molecular weight carriers can quite efficiently suppress B-cell responses, as will be discussed below Pfrengle et al. 2013 ).
CD22 and Siglec-G on B cells
Sialyltransferases and other enzymes involved in the synthesis of CD22 and Siglec-G ligands Since binding of ligands is important for CD22-and Siglec-Gmediated functions, as shown in the previous paragraph, further insights can be obtained from mouse models in which the enzymes creating these carbohydrate structures are deleted. Sialic acids are attached to glycans via α2,3, α2,6 or α2,8 linkages and these glycan modifications are generated by distinct enzymes. There exist four types of β-galactoside α2,3 sialyltrasferases (ST3Gal) in mice and α2,3Sia can be found on a great variety of cells (Kono et al. 1997) . 2,6Sia is less common and can be generated by several different enzymes (Takashima 2008) . The CD22 ligand is α2,6-linked sialic acid coupled to galactose and the ST6GalI sialyltransferase is the only enzyme which can produce these ligands and has been found to be expressed in hematopoetic and liver cells (Wang et al. 1993) . In contrast, Siglec-G ligands can be both 2,6Sia and 2,3Sia and are therefore generated by different types of sialyltransferases (Duong et al. 2010) .
ST6GalI-deficient mice lack CD22 ligands and phenocopy CD22 knockin mice with mutated ligand-binding domains (CD22-R130E mice) in several ways. They show impaired BCR-induced Ca2+ signaling and show an increased binding of CD22 to mIgM. As a consequence, CD22 is higher phosphorylated and more SHP-1 is recruited (Collins, Smith, et al. 2006; Ghosh et al. 2006; Grewal et al. 2006) . Thus, although the lack of 2,6Sia on cellular surfaces may affect many proteins and many physiological processes, ST6GalI-deficient mice show a B-cell restricted phenotype, which seems to affect mainly the function of CD22. This CD22-restricted function of the enzyme was indicated by generation of ST6GalI × CD22 double-deficient mice, which show an increased Ca2+ flux, comparable with CD22-deficient mice (Collins, Smith, et al. 2006; Ghosh et al. 2006) (Table I ). This demonstrates that loss of CD22 is dominant and enhances B-cell signaling even in ST6GalI-deficient B cells. In contrast to CD22-deficient and CD22 knockin mice with mutated ligand-binding domains, ST6GalI-deficient mice show strongly impaired immune responses to both T-cell dependent and T-cell independent immunizations (Hennet et al. 1998) . The mechanism for this impairment is unclear because impaired Ca2+ signaling cannot explain this phenotype. Of note, also CD22 × Siglec-G doubledeficient mice have a weaker T-cell dependent immune response (Jellusova, Wellmann, et al. 2010 ). This could indicate that 2,6Sia ligand binding of both Siglecs in germinal centers is important for these responses.
An enzyme that is also involved in generating CD22 and Siglec-G ligands is the CMP-Neu5Ac hydroxylase (Cmah). In mice, sialic acids occur in two forms, Neu5Ac and Neu5Gc, which vary just in one oxygen atom at the C5 position. The enzyme Cmah is responsible for this modification and transforms Neu5Ac to Neu5Gc (Naito et al. 2007) . Humans have lost this enzyme during evolution and therefore exclusively produce Neu5Ac. While human CD22 can bind to both forms of sialic 
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acids, murine CD22 prefers binding to Neu5Gc. Both human Siglec-10 and mouse Siglec-G prefer Neu5Gc binding. The monoclonal antibody GL7 has been found to specifically bind to Neu5Ac sialic acids in 2,6 linkage (Naito et al. 2007 ). This is of importance because GL7 is a widely used marker for murine germinal center B cells. It has also been found that LPS-stimulated B cells can be stained with GL7. These data indicate that the ligands Neu5Gc, preferred by murine CD22 and Siglec-G, are downregulated upon activation of B cells. Accordingly, it was found that the expression of Cmah is strongly reduced in germinal center B cells and binding of mCD22-Fc protein (a fusion protein consisting of the N-terminal domain of CD22 fused to human IgG Fc) is diminished. Whether this reduction of Siglec ligands in germinal center B cells is functionally relevant for B-cell antibody responses is still unknown because Cmah-deficient mice show normal T-cell dependent immune responses (Naito et al. 2007 ). Interestingly, activated T cells also downregulate Cmah and lose the Neu5Gc species on the surface. Recently, published in vitro (non-antigen-specific) binding experiments between B cells and T cells showed that Cmah−/− B cells could bind better to T cells than WT B cells ). This effect was CD22 dependent, as was shown by Cd22−/− mice and was explained by a loss of cis-ligand interactions and the availability of trans-interactions to T cells via CD22. Thus, activated B cells may be able to bind to naïve T cells by this mechanism, but not to activated T cells, such as to Tfh cells in the germinal center when a non-cognate interaction between B and T cells is not favorable.
A common sialic acid modification is O-acetylation at the C9 position. This modification prevents CD22 binding to sialic acids, as has been shown in vitro (Sjoberg et al. 1994) . It is assumed that this acetylation similarly affects Siglec-G binding. The enzyme which creates these modifications, a sialic acid O-acetyl transferase is still not clearly identified. The human Cas1 protein was described as a possible sialic acid-specific O-acetyl transferase, but it has to be confirmed whether this enzyme modifies CD22-or Siglec-G ligands (Arming et al. 2011) . In contrast, the enzyme sialic acid O-acetyl esterase (Siae), which can remove acetyl groups from the 9-O position of sialic acids, is well characterized. Siae activity thus leads to creation of more CD22 and Siglec-G ligands. The phenotype of Siae-deficient mice resembles the phenotype of CD22-deficient mice (Cariappa et al. 2009 ). Ca2+ signaling is increased, MZ B cells and recirculating B cells are decreased in these mice. The increase of Ca2+ signaling in Siae−/− B cells is surprising, as these mice should phenocopy ST6GalI−/− mice because in both cases CD22 and Siglec-G ligands are reduced. ST6GalI mice showed impaired Ca2+ signaling due to stronger CD22-IgM interaction (Collins, Smith, et al. 2006 ); however, this interaction was not studied in Siae−/− mice (Table I) . Furthermore, Siae-deficient mice develop autoimmunity, as will be discussed below.
Another modification of 2,6-linked sialic acids is sulfation at the C6-position of GlcNAc which affects CD22 binding. It was first shown on glycan arrays that human CD22 prefers this sulfated ligand, compared with the unsulfated ligand . Later, it was described that human B lymphocytes and endothelial cells express this sulfated CD22 ligand (Kimura et al. 2007 ). This expression pattern of the α2,6 sialic acid 6-sulfo-GlcNAc ligand makes it likely that the interaction of human CD22 to this high-affinity ligand also plays a role in vivo.
The role of CD22 and Siglec-G in tolerance and autoimmunity
It is very important to regulate B-cell tolerance, as 30-40% of human peripheral B cells can recognize self-antigens (Wardemann et al. 2003) . Self-reactive responses must be avoided and inhibitory receptors play an important role in this process. Siglecs bind to sialic acids that can be regarded as "self-structures" because they are abundantly expressed in vertebrates, but normally lacking on pathogen surfaces. Thus, it was expected that a loss of inhibitory, self-structure-binding Siglecs on B cells may lead to development of autoimmunity. Three out of four independently generated CD22-defcient mouse strains did not show this (Otipoby et al. 1996; Sato et al. 1996; Nitschke et al. 1997) . However, in one strain, which was on a mixed 129/ C57BL/6 (B6) background, high-affinity antibodies were produced (O'Keefe et al. 1999) . Similarly, when CD22-deficiency was crossed to autoimmune-prone strains, such as Y-linked autoimmune accelerator an increased autoimmunity was observed (Mary et al. 2000) . Some lupus-prone mouse strains, such as NZW or BXSB strains express the allelic CD22 a form, which has an impaired ability to bind to 2,6Sia (Lajaunias et al. 1999) . Backcrossing the CD22 a allele into the B6 background resulted in preactivated B cells . All these experiments showed that loss of CD22 on its own cannot cause autoimmune disease but can increase the susceptibility.
Also Siglec-G-deficient mice did not develop autoimmunity spontaneously. No high-affinity IgG autoantibodies were detected. They just developed autoantibodies of the IgM class including rheumatoid factor and anti-erythrocyte antibodies (Hoffmann et al. 2007 ). Several autoimmune-prone mouse strains, such as NZB/W or NZB, have an enlarged population of B-1 cells and this population produces IgM that is to some extent self-reactive. Therefore, this enlarged population in autoimmune-prone mouse strains was discussed to be important for development of autoimmune disease (Duan and Morel 2006) . Siglec-G-deficient mice do not support this hypothesis, as B-1 cells are increased to a similar extent as in the autoimmune-prone strains, but autoimmune disease does not develop (Hoffmann et al. 2007) . Instead, the self-reactive natural IgM produced by B-1 cells is also regarded to be important for house-keeping functions, such as clearance of apoptotic cells (Baumgarth 2011) . However, when arthritis was induced in the collagen-induced arthritis model, Siglec-G-deficient mice showed an earlier incidence and more severe arthritis than control mice (Bökers et al. 2014) . Similarly, when Siglec-G deficiency was crossed into the MRL/lpr background (which is a common lupus model), an earlier and more severe lupus disease was observed (Bökers et al. 2014 ). This increased severity was accompanied by an earlier occurrence of highaffinity IgG autoantibodies. Apparently, B-1 cells played no role in this earlier onset and more pronounced autoimmune disease, as this population was found in almost normal numbers, compared with control MRL/lpr mice. These results indicate that Siglec-G deficiency can increase the susceptibility CD22 and Siglec-G on B cells and severity of autoimmune diseases. It should be noted that Siglec-G is also expressed on the surface of dendritic cells and a loss of Siglec-G on these cells has been implicated to increase severity in a hepatocyte inflammation model and in bacterial sepsis (Chen et al. 2009; Chen et al. 2011 ). This is not part of this review, which concentrates on B cells, but is covered by Chen (accompanying review in this journal).
In contrast to single-deficient mice, CD22 × Siglec-G doubledeficient mice develop significant levels of IgG autoantibodies, IgG immune complex kidney deposition and glomerulonephritis indicating a lupus-like disease (Jellusova, Wellmann et al. 2010 ). This indicates that both Siglecs on B cells have redundant functions. Both are involved in the maintenance of B-cell tolerance, but the loss of one B-cell Siglec can still be functionally compensated by the presence of the other Siglec. Is the ligand-binding function of Siglec-G and CD22 involved in this maintenance of B-cell tolerance? A direct link to autoimmunity has also been found for Siae, the enzyme which modifies CD22 and Siglec-G sialic acid ligands. Siae−/− mice spontaneously develop a lupuslike disease (Cariappa et al. 2009 ). Also, rare variants in the human SIAE gene, which lead to functional impairment of the enzyme, are associated with several autoimmune diseases (Surolia et al. 2010) . In genome-wide association studies, the CD22 or SIGLEC10 genes have not been found to be associated with autoimmune diseases such as SLE. However, SNPs in genes of the Siglec downstream inhibitory signaling pathways, such as LYN or BLK have been associated with SLE (Harley et al. 2009; Cui et al. 2013 ). All these data can be summarized in a model that CD22 and Siglec-G contribute to B-cell tolerance by binding sialic acid self-ligands in trans (Figure 2 ). This may be relevant when the B cell recognizes a cell-bound or cell surface expressed autoantigen on a neighboring cell. Additional binding of CD22 and Siglec-G to 2,6Sia and 2,3Sia containing glycoproteins in trans may recruit more of these Siglec molecules into the vicinity of the BCR, thereby increasing the inhibitory signal. Once both Siglec proteins and crucial trans-ligands are lacking a break of B-cell tolerance can occur.
CD22 and Siglec-G as therapeutic targets
CD22 is as a pan B-cell marker expressed on the surface of most B-cell lymphomas and leukemias. CD22 has therefore been a target for antibody-based therapies. Upon antibody binding, CD22 shows an efficient endocytosis (O'Reilly et al. 2011) . Therefore, this can be used to target malignant B cells with antibody-bound bacterial or plant toxins. Such CD22-specific immunotoxins have been successfully used in phase I clinical studies for hairy cell leukemia (Kreitman et al. 2005) . Also other agents such as RNases have been coupled to anti-CD22 antibodies to target B cells (Krauss et al. 2005 ). CD22 has also been successfully targeted by the humanized anti-CD22 antibody epratuzumab that has been used in clinical trials of B-cell Non-Hodgkin lymphoma patients (Leonard and Goldenberg 2007) . Since B cells also play an important role in the progression of SLE, epratuzumab has also been used successfully in a clinical phase I/II trial for SLE (Wallace et al. 2014) . In contrast to other B-cell-directed therapies, B cells were hardly depleted by epratuzumab in SLE patients. This antibody seems to modulate B-cell signaling, by increasing the inhibitory function of CD22 and decreasing B-cell Ca2+ responses (Sieger et al. 2013) .
In addition to anti-CD22 antibodies high-affinity synthetic CD22 ligands have been developed by a structure-based design, based on the known structure of the Siglec-binding first Ig domain of Siglec-1 with its ligand. Biphenyl groups were attached to the C-9 position of sialic acids in two different chemical linkages and bound with increased affinity (IC50: 4 μM instead of 1.4 mM of the natural ligand Neu5Ac) and high specificity to CD22 (Kelm et al. 2002) . The compound BPC (biphenyl carbonyl)-Neu5Ac showed a high specificity for human (h)CD22, whereas BPA (biphenyl-acetyl)-Neu5Ac or BPA-Neu5Gc was highly specific for murine (m)CD22. Linking BPA-Neu5Gc in 2,3 or 2,6 linkage to lactose could then be used to generate high-affinity ligands with specificities for Siglec-G or murine CD22, respectively (Chen et al. 2010; Macauley et al. 2013; Pfrengle et al. 2013) . Several labs in the following time modified the hCD22-specific BPC-Neu5Ac ligands further by additional modifying the C-2 position of the sialic acid, the C-4 position or the combined C-2 and C-5 position of sialic acids, reaching higher affinities (IC 50: 50-100 nM) (Abdu-Allah et al. 2009 , 2011 Mesch et al. 2011; Kelm et al. 2013) . Recently, combined modifications at the C-2, C-3, C-4, in addition to the BPC-group at C-9 were shown to even further increase the affinity for hCD22 to 2 nM. This synthetic sialoside then reaches an affinity that is 7.5 × 10 5 times higher than the natural monomeric ligand Neu5Ac (Prescher et al. 2014) .
Why is there so much interest in designing and improving high-affinity sialoside ligands? The natural sialic acids bind CD22 in the millimolar affinity range, which is a weak affinity. The hope is that with nanomolar ligands for CD22 B-cell signaling of normal B cells can be modulated or that toxic agents can be introduced into malignant B cells by endocytosis. The latter approach has been shown for B-cell lymphoma cell lines with oligo-or dimeric variants of BPC-Neu5Ac which were able to kill these lymphoma cells in a CD22-specific way (Collins, Blixt, et al. 2006; Schweizer et al. 2013) . High-affinity CD22 ligands can enhance B-cell Ca2+ signaling, apparently by blocking the inhibitory function of CD22. The exact mechanism for this effect is not known (Kelm et al. 2002) . But the higher the affinity the lower concentrations of the synthetic sialosides are needed for this signal modulation (Schweizer et al. 2013; Prescher et al. 2014) . Recently, it has been shown that BPA-Neu5Gc in 2,6 linkage to lactose coupled to liposomes can suppress mouse antibody responses to protein antigens which were also attached to the same liposomes. This suppression was CD22 specific . Similarly, when BPA-Neu5Gc was coupled in 2,3 linkage to liposomes this could suppress antibody responses in a Siglec-G-specific way ). This shows that both Siglecs on B cells can be targeted specifically by liposomes containing both ligands and antigens. This approach has a future therapeutic potential for treatment of autoimmune diseases in an autoantigenspecific fashion (Nitschke 2013) .
Conclusion
CD22 and Siglec-G are two potent inhibitors of B-cell signaling. Genetic approaches have provided evidence that this inhibition of L Nitschke BCR signaling is dependent on cis-ligand binding to sialic acids in specific linkages. The ligand-binding activity of CD22 leads to homo-oligomer formation, which are to a large extent found in membrane domains distinct to those of the BCR. In contrast, Siglec-G is recruited via sialic acid binding to the BCR. This interaction of Siglec-G to mIgM leads to an inhibitory function that is much more pronounced in B-1 cells. The molecular details for this interaction are still not completely understood. Both CD22 and Siglec-G are guards of B-cell tolerance and loss of these proteins or its inhibitory pathways can increase the susceptibility for autoimmune diseases. CD22 is a target protein both in B-cell leukemias and lymphomas, as well as in B-cell-mediated autoimmune diseases. Both antibodies and synthetic chemically modified sialic acids are currently tested for this purpose.
